# Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

> **NCT02808104** · PHASE2 · COMPLETED · sponsor: **NLS Pharmaceutics** · enrollment: 84 (actual)

## Conditions studied

- Attention Deficit Disorder With Hyperactivity

## Interventions

- **DRUG:** mazindol

## Key facts

- **NCT ID:** NCT02808104
- **Lead sponsor:** NLS Pharmaceutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2017-03-28
- **Final completion:** 2017-03-28
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2017-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02808104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02808104, "Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02808104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*